Drugmaker Mylan's decision to "gouge" consumers on lifesaving EpiPen devices is corporate "greed on steroids," Ralph Nader told CNBC on Thursday.

"This is an old product. It's been around for years. It's not a brand new invention that's going to be amortized in terms of research and development," the consumer advocate said on "Squawk on the Street."